Ardent Health Inc. (ARDT)

FundamentalScore 3/5 (Mixed): ARDT appears inexpensive on enterprise multiples (EV/Sales ~0.49; EV/EBITDA ~7.75) with strong trailing free-cash-flow yield (~19%) and adequate liquidity (current ratio ~2.10; interest coverage ~9.7x). But margins are slim (TTM net margin ~1.22%) and the latest quarter disclosed in the 8-K exhibit shows softer trends (Q2 2026 revenue -1.4% YoY; adjusted EBITDA -32.3% YoY), creating near-term uncertainty. Recent filings do not indicate a going-concern issue or a disclosed covenant breach.

The dominant driver is the Aug 4 Q2 2026 print — EPS miss and lowered guidance (announced confidence) with a follow-on Zacks Strong Sell screen and FY estimate cuts, and no bullish catalyst offsetting it in window; the sentiment delta is indeterminate (30–90d baseline analyzer config-blocked) and the retail signal is empty. Moderate red-flag cap applied: court-docketed securities class action (26-cv-00022, M.D. Tenn.) plus negative in-window sentiment with no offsetting bullish catalyst.

Score 3/5: constructive intermediate and long-term trend — price 10.94 sits above the SMA50 (10.63) and SMA200 (9.51) with a very strong ADX14 of 47.10 confirming trend strength after the recovery from the June 3 plunge low (7.71) to the August 7 high (11.89). However the short-term tape is corrective: price is below the SMA20 (11.04), EMA9 (11.00) and EMA21 (10.96), the MACD line (+0.10) has slipped below its signal (+0.14) with a negative histogram (-0.03), and RSI14 (55.05) with Williams %R (-36.67) are merely neutral. Mixed bullish/neutral — an intact uptrend in a 2-3 week shallow pullback, not a clean setup.